Despite positive clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing considerable opposition from PBMs. The companies are often building obstacles to access, including high price requirements and PA that hinder patient availability. Industry believe that the coverage hurdles pr